Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time.
作者信息
Tung Norint P, Ma Joseph D
机构信息
Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, 0657, USA.
出版信息
Eur J Clin Pharmacol. 2022 Nov;78(11):1863-1864. doi: 10.1007/s00228-022-03386-z. Epub 2022 Sep 13.
Abstract
摘要
相似文献
1
Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time.内源性4β-羟基胆固醇作为评估细胞色素P450 3A（CYP3A）活性生物标志物的效用：尚未完全准备好进入黄金时期。
Eur J Clin Pharmacol. 2022 Nov;78(11):1863-1864. doi: 10.1007/s00228-022-03386-z. Epub 2022 Sep 13.
2
Response to: "Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time".对《内源性4β-羟基胆固醇作为评估细胞色素P450 3A（CYP3A）活性生物标志物的效用：尚未完全准备好进入黄金时代》的回应
Eur J Clin Pharmacol. 2022 Nov;78(11):1865-1866. doi: 10.1007/s00228-022-03387-y. Epub 2022 Sep 13.
3
Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.评价 4β-羟胆固醇和 25-羟胆固醇作为 CYP3A4 内源性生物标志物的研究：用 CYP3A 人源化小鼠进行的研究。
AAPS J. 2018 Apr 9;20(3):61. doi: 10.1208/s12248-018-0186-9.
4
4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.4β-羟基胆固醇作为 CYP3A 活性的内源性生物标志物：文献综述与批判性评价。
J Clin Pharmacol. 2019 May;59(5):611-624. doi: 10.1002/jcph.1391. Epub 2019 Feb 12.
5
Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.观点：4β-羟基胆固醇作为肝 CYP3A 的新兴内源性生物标志物。
Drug Metab Rev. 2017 Feb;49(1):18-34. doi: 10.1080/03602532.2016.1239630. Epub 2016 Oct 20.
6
4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians.4β-羟基胆固醇是一种新的内源性CYP3A标志物：与韩国人、瑞典人和坦桑尼亚人的CYP3A5基因型、奎宁3-羟化作用及性别的关系。
Pharmacogenet Genomics. 2008 Mar;18(3):201-8. doi: 10.1097/FPC.0b013e3282f50ee9.
7
Recommendations on the Development of a Bioanalytical Assay for 4β-Hydroxycholesterol, an Emerging Endogenous Biomarker of CYP3A Activity.关于 4β-羟基胆固醇作为 CYP3A 活性内源性生物标志物的生物分析检测方法的建立建议。
AAPS J. 2016 Sep;18(5):1056-1066. doi: 10.1208/s12248-016-9949-3. Epub 2016 Jun 27.
8
4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys.4β-羟基胆固醇作为食蟹猴CYP3A活性的内源性生物标志物。
Drug Metab Dispos. 2014 May;42(5):839-43. doi: 10.1124/dmd.114.057224. Epub 2014 Mar 4.
9
4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.4β-羟基胆固醇，一种人体内 CYP3A4/5 活性的内源性标志物。
Br J Clin Pharmacol. 2011 Feb;71(2):183-9. doi: 10.1111/j.1365-2125.2010.03773.x.
10
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.性别和 CYP3A5 基因型影响总 CYP3A 活性：埃塞俄比亚人 CYP3A 活性高，CYP3A5 变异等位基因分布独特。
Pharmacogenomics J. 2011 Apr;11(2):130-7. doi: 10.1038/tpj.2010.16. Epub 2010 Mar 16.
引用本文的文献
1
Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.类风湿关节炎患者在持续接受白细胞介素 6 受体拮抗剂治疗期间细胞色素 P450 的活性。
Eur J Clin Pharmacol. 2023 Dec;79(12):1687-1698. doi: 10.1007/s00228-023-03578-1. Epub 2023 Oct 13.
本文引用的文献
1
Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.4β-羟胆固醇与肝和肠道 CYP3A4 的相关性：在广泛体重范围内的患者中的蛋白表达、离体 microsomal 活性和体内活性。
Eur J Clin Pharmacol. 2022 Aug;78(8):1289-1299. doi: 10.1007/s00228-022-03336-9. Epub 2022 Jun 1.
2
4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.4β-羟基胆固醇作为 CYP3A 活性的内源性生物标志物：文献综述与批判性评价。
J Clin Pharmacol. 2019 May;59(5):611-624. doi: 10.1002/jcph.1391. Epub 2019 Feb 12.
3
Was 4β-hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?4β-羟基胆固醇会成为CYP3A4活性的有用标志物吗？
Br J Clin Pharmacol. 2018 Jul;84(7):1620-1621. doi: 10.1111/bcp.13538. Epub 2018 Feb 21.
4
Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.
Drug Dev Ind Pharm. 2016;42(6):945-57. doi: 10.3109/03639045.2015.1096278. Epub 2015 Oct 15.
5
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach.人类药物代谢酶和转运体的适当表型分析程序及其在“鸡尾酒”法中的同时应用。
Clin Pharmacol Ther. 2007 Feb;81(2):270-83. doi: 10.1038/sj.clpt.6100050.
6
Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants.除环孢素外：其他免疫抑制剂有限采样策略的系统评价
Ther Drug Monit. 2006 Jun;28(3):419-30. doi: 10.1097/01.ftd.0000211810.19935.44.
7
Problems and perspectives of phenotyping for drug-metabolizing enzymes in man.人类药物代谢酶表型分析的问题与前景
Int J Clin Pharmacol Ther. 2000 Jan;38(1):1-9. doi: 10.5414/cpp38001.
8
Noninvasive tests of CYP3A enzymes.CYP3A酶的非侵入性检测
Pharmacogenetics. 1994 Aug;4(4):171-84. doi: 10.1097/00008571-199408000-00001.
9
Some suggestions for measuring predictive performance.一些关于衡量预测性能的建议。
J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12. doi: 10.1007/BF01060893.
10
Statistical methods for assessing agreement between two methods of clinical measurement.评估两种临床测量方法之间一致性的统计方法。
Lancet. 1986 Feb 8;1(8476):307-10.
Zotero 插件